Abstracts tagged "Mortality"

Abstract Number: 0708 • ACR Convergence 2024
Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Vangala Adarsh¹, dihowm Fatma¹, Eyerusalem Akpan², Meredith Keller², Maheswari Muruganandam², N. Suzanne Emil², Frank O'Sullivan³, Roderick Fields² and wilmer sibbitt¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose: Use of high dose corticosteroids in systemic sclerosis (SSc) is considered a significant risk factor for development of scleroderma renal crisis (SRC). Intravenous (IV)…
Abstract Number: 1908 • ACR Convergence 2024
Male Sex, Medical Comorbidity and Post-procedure Complications Are Associated with Higher In-hospital Mortality After Primary Total Knee Arthroplasty for Osteoarthritis
Sumanth Chandrupatla¹, Kranti Rumalla² and Jasvinder Singh³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Baylor College of Medicine, Birmingham, AL
Background/Purpose: We aimed to assess whether sex, comorbidity and postoperative complications are associated with in-patient mortality after primary total knee arthroplasty (TKA) for osteoarthritis (OA).Methods:…
Abstract Number: 2454 • ACR Convergence 2024
Age-Adjusted Mortality Rate Trends in Systemic Sclerosis in the United States from 1999 to 2020
Ansaam Daoud¹, Loai Dweik², Muhammad Shamim³, Haseeb Chaudhary⁴ and Omer Pamuk⁵, ¹Case Western Reserve University/University Hospitals, Akron, OH, ²Cleveland Clinic Akron General Internal Medicine, Akron, OH, ³University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ⁴Case Western Reserve University, Westlake, OH, ⁵University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Of all rheumatic diseases, systemic sclerosis (SSc) has the highest disease-specific mortality, with a higher mortality risk than the general population. North America has…
Abstract Number: 0202 • ACR Convergence 2024
Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei¹, Hui Zhao¹, Suja Rajan³, Heather Lin¹ and Sharon Giordano¹, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson, Houston, TX, ³The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
Abstract Number: 0717 • ACR Convergence 2024
Associations Between Calendar Time and Age at Diagnosis with Mortality in a National Cohort of Veterans with ANCA-Associated Vasculitis from 2001-2020
Jennifer Hanberg¹, Svetlana Eden², Amy Anderson-Mellies², Suman Kundu², Matthew Freiberg², Zachary Wallace³ and Evelyn Hsieh⁴, and the Veterans Aging Cohort Study Project Team, ¹Brigham and Women's Hospital, Boston, MA, ²Vanderbilt University Medical Center and Tennessee Valley VA, Nashville, TN, ³Massachusetts General Hospital, Newton, MA, ⁴Yale School of Medicine / VA Connecticut Healthcare System, West Haven, Connecticut, New Haven, CT
Background/Purpose: It is not clear whether advances in ANCA-associated vasculitis (AAV) management between 2001-2020 have translated to improvement in population-level outcomes, including among older adults.…
Abstract Number: 1995 • ACR Convergence 2024
Use of Abatacept for the Treatment of Severe Immune-related Adverse Events from Immune Checkpoint Inhibitors for Cancer: A Case Series
Kaitlin McCarter¹, Xiaosong Wang², Senada Arabelovic¹, Nicole LeBoeuf¹, Elizabeth Buchbinder³, Lydia Gedmintas¹, Lindsey MacFarlane⁴, Deepak Rao⁵, Nancy Shadick², Elad Sharon³, Brittany Weber⁶, Anju Nohria¹, Ellen Gravallese⁷ and Jeffrey Sparks⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Dana Farber Cancer Institute, Boston, MA, ⁴Brigham and Women's Hospital, Hanover, NH, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) antagonize CTLA-4, PD-1, PD-L1, and Lag-3 to stimulate the immune system to treat cancer but may also cause immune-related adverse…
Abstract Number: 2456 • ACR Convergence 2024
High Levels of Circulating IFNα Are Associated with Increased Mortality in Patients with Diffuse Cutaneous Systemic Sclerosis
François Maillet¹, Carine Schmidt¹, Vincent Bondet², Alexandre Bense¹, Darragh Duffy³, Luc Mouthon¹, Mathieu Paul Rodero⁴ and Benjamin Chaigne⁵, ¹AP HP, Paris, France, ²INSERM PAsteur Institute, Paris, France, ³Inserm Pasteur Institue, Paris, France, ⁴Université Paris CIté, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Faculté des Saint-Pères, Paris, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by skin and organ fibrosis, autoimmunity, and vasculopathy. Although its pathophysiology remains unclear, recent data…
Abstract Number: 0333 • ACR Convergence 2024
Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
shiri keret¹, Raisa Silva², Irada Choudhuri², Eugenia Gkiaouraki³, Tanya Chandra⁴, Nantakarn Pongtarakulpanit⁵, shreya Sriram³, silvia Martinez Laverde³, Dana Ascherman³, Siamak Mogahadam⁵, Chester Oddis⁵ and Rohit Aggarwal⁶, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Lung involvement is the most common and severe extra-muscular manifestation of Idiopathic Inflammatory Myopathies (IIM). Early identification of patients at risk for lung transplant…
Abstract Number: 0733 • ACR Convergence 2024
Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)
Sai Shanmukha Sreeram Pannala¹, fares Saliba², Medha Rajamanuri³ and Veena Katikineni⁴, ¹Staten Island University Hospital, Northwell Health, staten island, new york city, NY, ²Staten Island University Hospital, Staten Island, NY, ³Southern Illinois University School of Medicine, Springfield, IL, ⁴Providence, Victorville, CA
Background/Purpose: Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a heterogeneous group of rare autoimmune conditions characterized by inflammation of blood vessels, leading to various clinical…
Abstract Number: 2031 • ACR Convergence 2024
A Contemporary Assessment of the Burden of Malignancy in IgG4-Related Disease
Grace McMahon¹, Isha Jha¹, Guy Katz¹, Cory Perugino¹, Ana Fernandes¹, John Stone² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital , Harvard Medical School, Concord, MA, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a fibro-inflammatory disorder that can affect nearly any organ. Because of the often tumefactive nature of IgG4-RD and its typical…
Abstract Number: 2467 • ACR Convergence 2024
Elderly Systemic Sclerosis. Clinical Presentation and Outcome
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³, Ismael Gonzalez⁴, Ignacio Gonzalez Fernandez⁵, Carolina Díez Morrondo⁵, Carolina Alvarez Castro⁶, Paula Perez Garcia⁵, Jose Ordas Martínez⁵, Pedro Baenas Gonzalez⁵ and elvira Diez álvarez⁵, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, León, Spain, ⁵Complejo Asistencial Universitario de Leon, Leon, ⁶Complejo Asistencial Universitario de Leon, Leon, Spain
Background/Purpose: Immunosenescence refers to the gradual deterioration of the immune system associated with aging, leading to an increased incidence of infections, cancer, and autoimmune diseases.…
Abstract Number: 0339 • ACR Convergence 2024
Clinical Characteristics Associated with Inpatient Mortality in Dermatomyositis Patients: A Single Center Retrospective Cohort Study
Anjana Srikumar, Keon Niknejad, Maria Kaltchenko and Jun Kang, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease associated with higher rates of hospitalization, longer lengths of stay, higher mean hospitalization costs, and increased inpatient…
Abstract Number: 0986 • ACR Convergence 2024
State-and-County-Level Social Vulnerability Index and Trends in Systemic Lupus Erythematosus-Related Mortality in the U.S
Omer Pamuk¹, Ansaam Daoud², Hasan Cetin³ and Marina Magrey⁴, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²Case Western Reserve University/University Hospitals, Akron, OH, ³Cleveland Clinic Cole Eye Institute, Cleveland, OH, ⁴Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: Epidemiological studies have shown significant health disparities in systemic lupus erythematosus (SLE). The Centers for Disease Control and Prevention (CDC) developed the social vulnerability…
Abstract Number: 2129 • ACR Convergence 2024
Fracture Risk Assessment Tool (FRAX®) Scores Predict Mortality in Community-Dwelling Elderlies
Thiago Quadrante Freitas¹, Leonardo Olalla², Luana Machado³, Camille Figueiredo³, Liliam Takayama⁴, Valeria Caparbo³, Ricardo Oliveira⁵, Diogo Domiciano¹ and Rosa M R Pereira³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Quito, Ecuador, ³Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, SP, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵RDO DIAGNÓSTICOS MÉDICOS, São Paulo, SP, Brazil
Background/Purpose: The World Health Organization Fracture Risk Assessment Tool (FRAX®) was developed to estimate the 10-year absolute probability of osteoporotic fractures among the general population.…
Abstract Number: 2476 • ACR Convergence 2024
The Impact of Systemic Sclerosis Manifestations on Survival and Humanistic Burden: A Targeted Literature Review
vanessa smith¹, Zoe Marjenberg² and Elizabeth Volkmann³, ¹Ghent University Hospital, Gent, Belgium, ²Maverex Ltd, North Shields, United Kingdom, ³University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease with multiple disease manifestations, including cutaneous fibrosis, musculoskeletal inflammation, Raynaud phenomenon, calcinosis and digital ulceration. Internal…

« Previous Page
1
…
4
5
6
7
8
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].